Review: Magnesium is effective and safe for acute management of rapid atrial fibrillationPDF
ACP J Club. 2007 Nov-Dec;147:61. doi:10.7326/ACPJC-2007-147-3-061
Clinical Impact Ratings
Onalan O, Crystal E, Daoulah A, et al. Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation. Am J Cardiol. 2007;99:1726−32. [PubMed ID: 17560883]
In patients with rapid atrial fibrillation (AF), does magnesium therapy improve rate or rhythm control?
Data sources: MEDLINE, old MEDLINE, EMBASE/Excerpta Medica, CENTRAL, Web of Science, ISI Proceedings, Biosis Previews, CINAHL, and HealthSTAR (all to June 2005); abstracts from scientific meetings in the past 10 years; and reference lists.
Study selection and assessment: Randomized controlled trials (RCTs) that compared intravenous magnesium with routine care, placebo, or antiarrhythmic drugs in adults with chronic or paroxysmal AF and rapid ventricular rate. Studies of patients with postoperative AF were excluded. 9 RCTs met the selection criteria. 8 RCTs (n = 476, range of mean ages 56 to 73 y) that compared magnesium with placebo, verapamil, diltiazem, amiodarone, or ajmaline were included in the meta-analysis; 1 RCT (n = 86) was excluded because most patients had rheumatic heart disease and mean age (38 y) was much younger than in the other trials. Total dose of magnesium ranged from 1.2 to 10 g. Quality assessment of individual trials was based on the 5-point Jadad scale (4 RCTs had scores ≥ 3).
Outcomes: Success in achieving rate control (< 90 or 100 beats/min) or rhythm control measured at ≤ 24 hours (median 5 h); time to response; and adverse events.
Magnesium was more effective than placebo in achieving rate control but did not differ from placebo for rhythm control (Table). Magnesium was less effective than verapamil in achieving rate control (Table). For rhythm control, magnesium was more effective than verapamil or diltiazem and similarly effective to amiodarone or ajmaline (Table), although significant statistical heterogeneity was noted for the latter. Time to response was shorter with magnesium than with placebo or verapamil (weighted mean difference −7.0 h, 95% CI −9.3 to −4.7). Groups did not differ for adverse events (Table); the most common side effect reported with magnesium was a transient sensation of warmth and flushing.
In patients with rapid atrial fibrillation, magnesium is safe and more effective than placebo for rate control. Magnesium is less effective than calcium-channel blockers for rate control but more effective for rhythm control.
Source of funding: No external funding.
For correspondence: Dr. O. Onalan, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. E-mail email@example.com.
Table. Magnesium vs placebo or antiarrhythmic drugs in patients with rapid atrial fibrillation at ≤ 24 hours*
|Outcomes||Number of trials (n)||Comparison group||Weighted event rates||RBI/RBR/RRR (95% CI)||NNT/NNH (CI)|
|Rate control (< 90 or 100 beats/min)||3 (258)||Placebo||61% vs 35%||RBI 74% (33 to 128)||NNT 4 (3 to 8)|
|1 (45)||Verapamil||24% vs 58%†||RBR 59% (6 to 82)||NNH 3 (2 to 3)|
|Rhythm control||4 (273)||Placebo||24% vs 17%||RBI 41% (−11 to 124)||Not significant|
|2 (91)||Verapamil or diltiazem||57% vs 17%||RBI 231% (68 to 552)||NNT 3 (2 to 5)|
|2 (112)||Amiodarone or ajmaline||39% vs 48%||RBR 19% (−30 to 50)||Not significant|
|Adverse events||8 (476)||All||5.1% vs 9.1%||RRR 37% (−13 to 65)||Not significant|
*Abbreviations defined in Glossary. RBI, RBR, RRR, NNT, NNH, and CI calculated from data in article using a fixed-effects
†Unweighted event rate.
Magnesium has several effects on the heart that may be beneficial for patients with rapid AF, including prolongation of the refractory period of the atrioventricular node. Onalan and colleagues synthesized the data from previous studies to examine whether these biological effects are translated into clinically beneficial outcomes relative to placebo or active treatment. They used a rigorous search strategy to identify 9 RCTs and concluded that magnesium is effective and safe for the management of rapid AF. However, several limitations raise concerns about the strength of the conclusions. Most notably, comparing magnesium with placebo when active treatments are available is of questionable clinical relevance. Similarly, the importance of an outcome combining rate and rhythm control into an “overall response” is unclear. The small sample size of the aggregated data, wide variation in magnesium dosages, and marked heterogeneity among trials also limit confidence in the results. A further concern is the exclusion of a study (1), which found that a calcium-channel blocker was superior to magnesium for rate control, because of factors that were not prespecified as exclusion criteria for the meta-analysis.
The authors found that calcium-channel blockers improve rate control to a greater degree than does magnesium, confirming that these drugs, along with β-blockers and digoxin, will continue to be the primary means of improving rate control for most patients with AF (2). The finding that magnesium may be effective for rhythm control is provocative and given the safety of magnesium, warrants further study in a large randomized trial.
Andrew Dunn, MD
Mount Sinai School of Medicine
New York, New York, USA
1. Joshi PP, Deshmukh PK, Salkar RG. Efficacy of intravenous magnesium sulphate in supraventricular tachyarrhythmias. J Assoc Physicians India. 1995;43:529-31. [PubMed ID: 8772970]
2. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol. 2006;48:854-906. [PubMed ID: 16904574]